^
Association details:
| Biomarker: | BRAF V600E |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases
Excerpt:
...- RAS mutation and BRAF V600E wild-type;...
Trial ID:
Source:
Title:
First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer
Excerpt:
...- BRAF V600E mutant status of primary colorectal cancer and/or related metastasis;...
Trial ID:
More C2 evidence
Source:
Title:
Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis
Excerpt:
...Age 18-75 years; Histologically proven colorectal adenocarcinoma; Simultaneous liver-limited metastases; Initially unresectable liver metastases determined by a local MDT; Life expectancy of > 3 months; RAS mutation and BRAF V600E wild-type; ECOG 0-1; Available PET/CT imaging before treatment; Available colonoscopy biopsy specimens before treatment...
Trial ID:
Less C2 evidence
Source:
Title:
Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with Irinotecan Dose Escalation versus FOLFOXIRI Plus Bevacizumab in BRAFV600E-Mutant Metastatic Colorectal Cancer: The Preliminary Data from a Single-Center Observational Study
Published date:
12/01/2023
Excerpt:
Our findings indicate that FOLFIRI plus bevacizumab with irinotecan dose escalation is an effective first-line treatment regimen for patients with BRAFV600E-mutant mCRC. This regimen leads to acceptable clinical outcomes…
Secondary therapy:
FOLFIRI
DOI:
10.3390/medicina59122108
Source:
Title:
The effect of BRAFV600E mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer – A post-hoc exploratory analysis of the randomized NORDIC9-study
Published date:
09/18/2023
Excerpt:
Patients were randomized (1:1) to reduced-dose SOx (S1 (Teysuno), 20 mg/m2 orally twice daily and oxaliplatin 100 mg/m2 intravenously on day 1, q3w) or full-dose S1 monotherapy (30 mg/m2 orally twice-daily on days 1–14, q3w)....Kaplan-Meier curve demonstrating overall survival in patients harboring BRAFV600Emutation comparing reduced-dose SOx ± bevacizumab...Reduced-dose combination chemotherapy might be a promising first-line treatment option for vulnerable older patients with mCRC harboring BRAFV600E mutation.
Secondary therapy:
oxaliplatin + gimeracil/oteracil/tegafur
DOI:
https://doi.org/10.1016/j.jgo.2023.101632
Source:
Title:
Impact of encorafenib on survival of patients with BRAF V600E -mutant metastatic colorectal cancer in a real-world setting
Published date:
07/11/2023
Excerpt:
Most patients received a palliative doublet chemotherapy with FOLFOX or FOLFIRI in combination with bevacizumab as first line....we recommend the addition of bevacizumab to the first-line chemotherapy backbone based on the results we observed in our patient population. Patients who received a monoclonal antibody had a higher ORR, median PFS and median OS compared to patients treated with chemotherapy only....In conclusion, only a small number of patients with BRAFV600E mutant mCRC in a real-world setting qualify for the guideline recommended intensive first-line chemotherapy with FOLFOXIRI and are rather treated with a doublet chemotherapy in combination with bevacizumab.
Secondary therapy:
FOLFIRI; FOLFOX
DOI:
https://doi.org/10.21203/rs.3.rs-3143154/v1
Source:
Title:
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study
Published date:
06/23/2023
Excerpt:
Importantly, ORR in the cetuximab arm was markedly below the expected 82.5%, while the prespecified ORR of 60% for FOLFOXIRI plus bevacizumab was exceeded….On the contrary, FOLFOXIRI plus bevacizumab led to a significantly longer PFS, higher ORR, and longer OS when compared with the cetuximab arm. Bevacizumab-based chemotherapy, doublet or triplet according to treatment goal and patient tolerability, therefore remains the preferable first-line treatment of patients with BRAFV600E-mutant mCRC.
Secondary therapy:
FOLFOXIRI
DOI:
10.1200/JCO.22.01420
Source:
Title:
Real-world first-line treatment of patients with BRAFV600E-mutant metastatic colorectal cancer: the CAPSTAN CRC study
Published date:
11/08/2022
Excerpt:
The main first-line treatments were FOLFOX plus bevacizumab (27.1%) and FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, irinotecan) with/without bevacizumab (27.1%/19.2%)….Across all first-line regimens, progression-free survival (PFS) and overall survival were 6.0 [95% confidence interval (CI) 5.3-6.7] months and 12.9 (95% CI 11.6-14.1) months, respectively....This study is, to date, the largest real-world analysis of patients with BRAFV600E-mutant mCRC, providing valuable insights into routine first-line treatment practices for these patients.
Secondary therapy:
FOLFOX; FOLFOXIRI
DOI:
10.1016/j.esmoop.2022.100603
Source:
Title:
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
Published date:
06/03/2022
Excerpt:
A significant interaction effect between primary sidedness and treatment intensity was reported in terms of both PFS (p = 0.010) and OS (p = 0.003), with a beneficial effect of the triplet in the right-sided group...Real-life data support the use of FOLFOXIRI ± bevacizumab only in BRAFV600E-mutated mCRC patients with right-sided tumours.
Secondary therapy:
FOLFOXIRI
DOI:
10.1038/s41416-022-01852-0
Source:
Title:
WJOG13219G: Triplet versus doublet in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer: A multi-institutional real-world data analysis (BRACELET study).
Published date:
01/18/2022
Excerpt:
WJOG13219G was a multicenter, retrospective registry-based study of pts with BRAFV600E-mutant mCRC who received first-line doublet or triplet chemo with/out molecular targeted agents...In the subgroup analysis, pts with right-sided primary tumor in the Triplet group showed favorable trends of PFS (HR, 0.87; 95% CI, 0.65–1.16) and OS (HR, 0.71; 95%CI, 0.50–1.01), whereas pts with left-sided tumor in the Triplet group showed the reverse trends of PFS (HR, 1.17; 95% CI, 0.77–1.78) and OS (HR, 1.68; 95% CI, 0.97–2.91).
Secondary therapy:
FOLFOXIRI
Source:
Title:
Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116).
Published date:
05/19/2021
Excerpt:
FOLFOXIRI was combined with either bevacizumab (arm A)...Median PFS was significantly longer in arm A vs arm B (8.3 months vs 5.9 months; logrank p = 0.03; HR 1.8)….FOLFOXIRI plus either bevacizumab or cetuximab have comparable efficacy with differential effects according to primary tumor sidedness supporting the heterogeneity of BRAF V600E-mutant subpopulation of mCRC.
Secondary therapy:
FOLFOXIRI
DOI:
10.1200/JCO.2021.39.15_suppl.3502
Trial ID:
Source:
Title:
BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?
Published date:
02/18/2021
Excerpt:
CONTRADICTING EVIDENCE: Of 3380 patients enrolled from June 2009 to June 2020, 214 (13%) of 1657 with known status were BRAFmt: 127 (24%) of 524 RS and 87 (8%) of 1133 LS...Initial chemotherapy and bevacizumab produced a median PFS of 7.6 versus 11.6 months (p = 0.02) for LS BRAFmt (n = 36) versus LS BRAFwt (n = 438), respectively....LS BRAFmt cancers share many features with RS BRAFmt cancers, including poor survival outcomes.
Secondary therapy:
Chemotherapy
DOI:
10.1007/s11523-021-00793-7
Source:
Title:
Conversion Surgery After Encorafenib Plus Cetuximab for Chemorefractory BRAF V600E-mutated Colorectal Cancer With Para-aortic Lymph Node Metastases
Published date:
06/28/2023
Excerpt:
CONTRADICTING EVIDENCE: A 68-year-old woman was diagnosed with ascending colon cancer and multiple para-aortic lymph node metastases. After primary tumor resection, molecular genetic testing of the primary tumor revealed a BRAF V600E mutation. She was treated with FOLFOXIRI plus bevacizumab as first-line chemotherapy. After disease progression, the regimen was changed to encorafenib plus cetuximab, and the metastatic lesions shrank. She underwent para-aortic lymph node dissection as conversion surgery, and pathology revealed complete response of the lymph nodes. She achieved long-term survival.
Secondary therapy:
FOLFOXIRI
DOI:
10.21873/invivo.13269